An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia
Efficacy of Methoxy Poly-Ethylene Glycol Epoetin Beta (C.E.R.A.) for Correction of Anemia and Maintenance of the Hb Levels in CKD Patients in Stage III - IV, Not on Dialysis, Treated According to Routine Clinical Practice
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Bhubaneswar, India, 751021
-
Hyderabad, India, 500 029
-
Mumbai, India, 400012
-
Mumbai, India, 400036
-
Vadodara, India, 390005
-
Vellore, India, 632006
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult patients, 18 to 65 years of age, inclusive
- Patients with stage III-IV chronic kidney disease not on dialysis
- Erythropoiesis stimulating agent (ESA) naïve with Hb < 10 g/dL, or on treatment with ESAs other than Mircera and Hb within the target range of 10-12 g/dL
- Adequate iron status as judged by the treating physician
Exclusion Criteria:
- Hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study medication
- Clinically significant concomitant disease or disorder as defined by protocol
- Clinical suspicion of pure red cell aplasia (PRCA)
- Planned elective surgery during the study period , except for cataract surgery or vascular access surgery
- Transfusion of red blood cells in the previous 2 months
- Pregnant women
- Contraindications for Mircera according to local prescribing information or as judged by the investigator
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
C.E.R.A.
Participants with chronic renal anemia Stage III-IV, not on dialysis, will be administered Continuous Erythropoietin Receptor Activator (C.E.R.A.) according to routine clinical practice and will be followed up for the treatment duration of 24 weeks (6 months).
Dosing and titration of C.E.R.A. treatment will be at the discretion of the investigator in accordance with local clinical practice or prescribing information.
Dosing instructions as per the local label are - For correction of anemia: 0.6 microgram per kilogram (mcg/kg) of C.E.R.A. once every two weeks, and for Maintenance of hemoglobin (Hb) levels: Conversion to C.E.R.A. dose (120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks) depending on the previous weekly epoetin or darbepoetin dose.
|
Participants receiving 0.6 mcg/kg of C.E.R.A. once every two weeks for correction of anemia and conversion to C.E.R.A. dose 120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks for maintenance of Hb according to local clinical practice or prescribing information will be observed.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Height of Participants at Baseline (Week 0)
Time Frame: At Baseline (Week 0)
|
The mean body height of the participants was measured and summarized in centimeters (cm).
Baseline is defined as Week 0.
|
At Baseline (Week 0)
|
|
Mean Weight of Participants at Baseline (Week 0)
Time Frame: At Baseline (Week 0)
|
The mean body weight of the participants was measured and summarized in kg.
Baseline is defined as Week 0.
|
At Baseline (Week 0)
|
|
Number of Participants With Co-morbidities at Baseline (Week 0)
Time Frame: At Baseline (Week 0)
|
Co-morbidities were those medical disorders present in the medical history but unresolved at Baseline.
The number of participants with different co-morbidities is presented.
Baseline is defined as Week 0.
|
At Baseline (Week 0)
|
|
Mean Time to Achieve Target Hemoglobin Range (10-12 Gram/Deciliter)
Time Frame: Up to Week 24
|
Correction of anemia was evaluated in participants with Hb < 10 gram/deciliter (g/dL).
Hemoglobin levels were recorded for each participant at enrollment and at different time points during the study up to Week 24.
The mean time required to achieve target Hb range (10-12 g/dL) was calculated using the following formula: Time to achieve target range = (Date of Hb evaluation when participant achieves target range at first time - visit date of first dosing) + 1.
|
Up to Week 24
|
|
Percentage of Participants Maintaining Hemoglobin Level Within 1 Gram/Deciliter of Baseline Value
Time Frame: Up to Week 24
|
Maintenance of Hb levels was to be evaluated for participants on Erythropoiesis stimulating agent (ESA) with Hb levels 10-12 g/dL.
None of the participants in the enrolled population had received treatment with other ESAs and had pre-therapy Hb level as 10 g/dL or above.
Therefore, the percentage of participants who had received treatment with other ESAs and were maintaining Hb level within 1 g/dL of baseline value during the study could not be evaluated.
Baseline is defined as Week 0.
|
Up to Week 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Achieving Hemoglobin Target Range (10-12 Gram/Deciliter) at Least Once During the Study
Time Frame: Up to Week 24
|
Correction of anemia was evaluated in participants with Hb < 10 g/dL at enrollment.
Hemoglobin levels were recorded for each participant at enrollment and at different time points during the study up to Week 24.
The percentage of participants achieving the target Hb range (10-12 g/dL) at least once during the study is presented.
|
Up to Week 24
|
|
Mean Time Spent in the Hemoglobin Target Range (10 - 12 Gram/Deciliter)
Time Frame: Up to Week 24
|
The Hb concentration was recorded for all the participants at enrollment and different time points throughout the study up to Week 24.
The mean time spent (in weeks) by the participants in the target range (10 - 12 g/dL) is presented.
|
Up to Week 24
|
|
Mean Dose of C.E.R.A. Administered
Time Frame: Up to Week 24
|
The mean dose of C.E.R.A. administered during the study is reported.
This accounts for the study drug injected through subcutaneous route at a frequency of every 4 weeks or once a month and every 2 weeks or fortnightly.
|
Up to Week 24
|
|
Number of Doses of C.E.R.A. Administered by Different Routes
Time Frame: Up to Week 24
|
The number of doses of C.E.R.A. administered by the intravenous or subcutaneous route is presented.
The number of doses for total population is calculated by summation and presented in table below as per routes of administration.
|
Up to Week 24
|
|
Number of Participants Who Received Concomitant Treatment for Anemia
Time Frame: Up to Week 24
|
Medications that were used during the study treatment period (from the date of first dose of study medication to the end of the study) were included as concomitant medications.
The number of participants taking concomitant medications prescribed for the treatment of anemia (for example iron) is presented.
|
Up to Week 24
|
|
Number of Participants With Adverse Events and Serious Adverse Events
Time Frame: Up to Week 24
|
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Pre-existing conditions which worsened during this study were reported as AEs.
A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.
|
Up to Week 24
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ML25476
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.